Trials / Completed
CompletedNCT00668304
Trial to Evaluate Time to Symptom Relief and Elimination of Infecting Bacteria in Treating Sinusitis With Avelox
Prospective, Multicenter, Open, Uncontrolled Trial to Evaluate the Time to Bacterial Eradication and Key Symptom Relief in the Treatment of Acute Bacterial Maxillary Sinusitis With Moxifloxacin 400 mg QD
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 192 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluated the time to bacteriological eradication of common pathogens during moxifloxacin therapy for acute bacterial maxillary sinusitis. The study also examined the time to resolution of key symptoms associated with sinusitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avelox (Moxifloxacin, BAY12-8039) | Moxifloxacin 400 mg once orally daily |
Timeline
- Start date
- 2004-06-01
- Completion
- 2005-01-01
- First posted
- 2008-04-29
- Last updated
- 2014-12-19
Locations
35 sites across 2 countries: United States, Argentina
Source: ClinicalTrials.gov record NCT00668304. Inclusion in this directory is not an endorsement.